Journal
HEPATOLOGY
Volume 56, Issue 2, Pages 464-473Publisher
WILEY-BLACKWELL
DOI: 10.1002/hep.25661
Keywords
-
Categories
Funding
- Merck
- Abbott
- Bristol-Myers Squibb
- Excalenz
- Gilead
- GlobeImmune
- Hyperion
- Roche
- Sundise
- Ocera
- Vertex
- Conatus
- Idenix-Novartis
- Ikara
- Intercept
- Mochida
- Novartis
- Pfizer
- Pharmasset
- Zymogenetics
Ask authors/readers for more resources
Patients with chronic hepatitis C and insulin resistance are less likely to respond to anti-hepatitis C virus (HCV) therapy and are at risk for more rapid fibrosis progression. Coadministration of pioglitazone with peginterferon/ribavirin improves insulin sensitivity and increases virologic response rates in insulin-resistant HCV genotype 4 patients, but it is unclear whether this finding applies to genotype 1 patients. For this reason we randomized treatment-naive HCV genotype 1 patients with insulin resistance to receive either standard care (peginterferon alpha-2a plus ribavirin for 48 weeks, n = 73) or pioglitazone 30-45 mg/day plus standard care (n = 77) in an open-label multicenter trial. Patients randomized to pioglitazone received the drug during a 16-week run-in phase, the 48-week standard-care phase, and the 24-week untreated follow-up phase. Pioglitazone treatment improved hemoglobin A1c (HbA1c), plasma glucose, insulin levels, and homeostasis model assessment of insulin resistance score and increased serum adiponectin levels during the 16-week run-in phase and maintained these improvements during the standard-care phase. However, we observed no statistically significant difference between the two groups in the primary efficacy endpoint, the decrease from baseline to Week 12 of peginterferon alpha-2a/ribavirin treatment in mean log10 HCV RNA titer (-3.5 +/- 1.71 and -3.7 +/- 1.62 IU/mL in the pioglitazone and standard-care groups, respectively, triangle = 0.21 IU/mL, P = 0.4394). Conclusion: Treatment with pioglitazone before and during treatment with peginterferon alpha-2a plus ribavirin improved several indices of glycemic control in patients with chronic hepatitis C and insulin resistance, but did not improve virologic response rates compared with peginterferon alpha-2a plus ribavirin alone. (HEPATOLOGY 2012)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available